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Background:  Pitavastatin significantly improved lipid profiles and reduced serum high-sensitivity C-reactive protein (hs-CRP) levels in a multi-
center and prospective study, KISHIMEN. The aim of this study is to explore the effect of pitavastatin on circulating levels of soluble lectin-like 
oxidized LDL receptor-1 (sLOX-1), a biomarker for vulnerable atherosclerotic plaques, in a sub-analysis of KSHIMEN.
Methods:  This sub-analysis included 84 patients (age: 62.5 +/- 1.4, male: 52.4%, diabetes: 67.5%). Pitavastatin (1-2 mg/day) was administered 
for 12 months. Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL 
cholesterol (non-HDL-C), high-sensitivity C-reactive protein (hs-CRP) and sLOX-1 levels were measured.
Results:  Pitavastatin significantly lowered LDL-C and non-HDL-C by 27.4% and 26.9% (mean values), respectively. HDL-C levels also were 
significantly increased by 9.4%. Pitavastatin significantly reduced hs-CRP levels by 28.6% in the whole subjects and by 62.4% in the highest quartile 
of the baseline hs-CRP levels (median values). Pitavastatin significantly reduced sLOX-1 levels in the highest quartile by 45.3% (median values, 
p=0.027), although it did not significantly affect the sLOX-1 levels in the whole population. Blood sLOX-1 levels did not significantly correlate with 
hs-CRP, LDL-C, HDL-C or non-HDL-C levels at baseline or after pitavastatin treatment. Percent changes in sLOX-1 did not significantly correlate with 
those in hs-CRP, LDL-C, HDL-C or non-HDL-C. Presence or absence of diabetes did not significantly affect sLOX-1 values at baseline or after the 
treatment.
Conclusions:  Pitavastatin reduces elevated sLOX-1 levels, independently of improved lipid profiles or hs-CRP levels, in hypercholesterolemic 
subjects including diabetes.
